290 patents
Page 7 of 15
Utility
Methods for treating osteogenesis imperfecta
25 Jan 22
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).
Brendan Lee, Kuber T. Sampath
Filed: 1 Jul 19
Utility
Methods for Treating Symptoms and Disorders Associated with Lysosomal Storage Diseases
20 Jan 22
This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy.
Nigel Patrick Somerville CRAWFORD, Tanya Zaremba FISCHER
Filed: 3 Feb 20
Utility
Methods and Compositions for Treating a SERPINC1-ASSOCIATED Disorder
20 Jan 22
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
Filed: 14 Jul 21
Utility
Aav Virions with Decreased Immunoreactivity and Uses Therefor
20 Jan 22
Methods of making and using recombinant AAV virions with decreased immunoreactivity are described.
Alejandra E. ARBETMAN, Peter C. COLOSI, Michael A. LOCHRIE, Richard T. SUROSKY
Filed: 23 Jun 21
Utility
Anti-Human CD52 Immunoglobulins
13 Jan 22
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52.
Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
Filed: 3 Mar 21
Utility
Methods for the Quantitation of Polypeptides
6 Jan 22
Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.
Christopher MORGAN, Xiaokui ZHANG
Filed: 16 Jun 21
Utility
Assays for detecting the presence or amount of an anti-drug antibody
4 Jan 22
Methods and kits for detecting antibodies (e.g., anti-drug antibodies).
Ryan Grabert, Susan Richards, Valerie Theobald, Yuanxin Xu, Jad Zoghbi
Filed: 8 Aug 17
Utility
Recombinant glycoproteins and uses thereof
28 Dec 21
Provided herein are recombinant glycoproteins (e.g., recombinant human α-galactosidase-A proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins.
Karen Lee, Christopher Hwang, Christine DeMaria
Filed: 22 Oct 14
Utility
Methods and Compositions for Treating Hemophilia
23 Dec 21
The present disclosure provides using a double-stranded oligonucleotide compound as a novel therapy to improve the quality of life and joint function of patients with hemophilia A and hemophilia B.
Baisong Mei, Shauna Andersson, Qifeng Yu, Pronabesh DasMahapatra
Filed: 22 Jun 21
Utility
Inhibitors of Glucosylceramide Synthase
23 Dec 21
Hanlan LIU, Chris WILLIS, Renu BHARDWAJ, Diane P. COPELAND, Abizer HARIANAWALA, Jeffrey SKELL, John MARSHALL, Jianmei KOCHLING, Gerard PALACE, Judith PETERSCHMITT, Craig SIEGEL, Seng CHENG
Filed: 3 Sep 21
Utility
Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers
21 Dec 21
The present invention relates to methods for purifying or enriching a biomolecule using multimodal resins and an elution buffer containing a Good's buffer.
Rahul Godawat, Daniel Cummings, Veena Warikoo
Filed: 23 Dec 19
Utility
Biomarker of Polycystic Kidney Disease and Uses Thereof
9 Dec 21
Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient.
Nikolai Bukanov, Sarah Moreno, Timothy E. Weeden
Filed: 17 Aug 21
Utility
Rabbit Antibodies to Human Immunoglobulins G
9 Dec 21
This disclosure anti-human IgG antibodies and antigen-binding portions thereof derived from rabbits and methods of using these antibodies and portions.
Ruiyin CHU
Filed: 1 Jun 21
Utility
Inhibitors of T-cell Activation
9 Dec 21
The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
Filed: 3 May 21
Utility
Inhibitors of Glucosylceramide Synthase
2 Dec 21
Hanlan LIU, Chris WILLIS, Renu BHARDWAJ, Diane P. COPELAND, Abizer HARIANAWALA, Jeffrey SKELL, John MARSHALL, Jianmei KOCHLING, Gerard PALACE, Judith PETERSCHMITT, Craig SIEGEL, Seng CHENG
Filed: 7 Jan 21
Utility
Anti-αβTCR antibody
30 Nov 21
The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
Filed: 10 Jan 18
Utility
Methods for Preventing Retropulsion of Concretions and Fragments During Lithotripsy
18 Nov 21
One aspect of the present invention provides a method for the treatment of lithiasis, which mitigates the risk of damage to surrounding body tissue when removing a calculi (e.g., biological concretions, such as urinary, biliary, and pancreatic stones) that obstructs or may otherwise be present within a body's anatomical lumen.
Jean-Marie Vogel, James A. Wilkie
Filed: 26 Feb 21
Utility
Generation of Improved Human Pah for Treatment of Severe Pku by Liver-directed Gene Replacement Therapy
11 Nov 21
Provided herein are variant phenylalanine hydroxylase (PAH) polypeptides which are more stable and have greater activity than wild-type human PAH.
Sirkka KYOSTIO-MOORE, Partha MANAVALAN
Filed: 11 Oct 19
Utility
Glycoengineered antibody drug conjugates
2 Nov 21
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis Z. Avila, Qun Zhou
Filed: 6 Aug 18
Utility
Methods for Treating Gaucher Disease
28 Oct 21
Methods for treating Gaucher disease in patients with renal or hepatic impairment.
Jing LI, M. Judith PETERSCHMITT, Vanaja KANAMALURU, Jun CHEN, Sebastiaan J.M. GAEMERS, Dan RUDIN
Filed: 7 Dec 20